PLX4032 (RO 5185426) is an ATP competitive, orally administered BRAF inhibitor (wt BRAF IC50 100 nM) with high selectivity for the mutant allele (BRAFV600E IC50 31 nM) and has shown selective tumour suppression in mutant BRAF cell lines and xenograft models. This evidence concerns the gene BRAF and neoplasm.